Answers are grounded in this paper and cite their sources.
The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib.
No takes yet. Share an insight, caveat, or question.
Catenacci et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: